Form 4: Centessa Pharmaceuticals CEO Sells Shares Under 10b5-1 Plan

Centessa Pharmaceuticals CEO, Saurabh Saha, executed a sale of 87,496 ordinary shares at an average price of $18.4609, while also acquiring the same number of shares through option exercise at $5.84.

Summary

• Centessa Pharmaceuticals CEO, Saurabh Saha, engaged in transactions involving the company's ordinary shares on December 6, 2024.
• Mr. Saha acquired 87,496 ordinary shares through the exercise of share options at a price of $5.84 per share.
• Simultaneously, he sold 87,496 ordinary shares at a weighted average price of $18.4609 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 16, 2024.
• Following these transactions, Mr. Saha directly owns 575,661 ordinary shares and indirectly owns 38,000 shares through a trust.
• Mr. Saha also holds options to purchase 3,869,485 ordinary shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by the CEO under a pre-arranged plan. While the sale might cause some concern, the overall sentiment is neutral as it is a common practice.

Positives

• The exercise of options at a lower price ($5.84) and subsequent sale at a higher price ($18.4609) indicates a potential profit for the CEO.
• The use of a 10b5-1 trading plan suggests a structured and transparent approach to share transactions.

Negatives

• The sale of a significant number of shares by the CEO could be perceived negatively by some investors, potentially signaling a lack of confidence in the company's short-term prospects.

Risks

• The market may react negatively to the CEO's share sale, potentially impacting the stock price.
• The reliance on a pre-arranged trading plan may not fully reflect the CEO's current outlook on the company's performance.

Industry Context

This type of transaction is common for executives who receive stock options as part of their compensation. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice in the pharmaceutical industry.
• Many CEOs in similar companies use 10b5-1 plans to manage their stock transactions.
• The specific prices and volumes of these transactions are unique to the individual and the company's stock performance.

Stakeholder Impact

• Shareholders may react to the CEO's share sale, potentially impacting the stock price.
• Employees may view the transaction as a sign of the CEO's personal financial strategy.

Key Dates

Keywords

Centessa Pharmaceuticals, Saurabh Saha, share sale, insider trading, Rule 10b5-1, share options, executive compensation, CNTA